Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells

BACKGROUND: Identification and validation of a targeted therapy for triple-negative breast cancer (TNBC), that is, breast cancers negative for oestrogen receptors, progesterone receptors and HER2 amplification, is currently one of the most urgent problems in breast cancer treatment. EGFR is one of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Caiazza, F, McGowan, P M, Mullooly, M, Murray, A, Synnott, N, O'Donovan, N, Flanagan, L, Tape, C J, Murphy, G, Crown, J, Duffy, M J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580380/
https://www.ncbi.nlm.nih.gov/pubmed/26010411
http://dx.doi.org/10.1038/bjc.2015.163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580380/
https://www.ncbi.nlm.nih.gov/pubmed/26010411
http://dx.doi.org/10.1038/bjc.2015.163

Ejemplares similares